Gossamer Bio Announces Appointment of Luisa Salter-Cid, Ph.D. as Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)--Sep 5, 2018--Gossamer Bio, Inc. (“Gossamer Bio”) today announced that Luisa Salter-Cid, Ph.D. will join its executive management team as Chief Scientific Officer. Dr. Salter-Cid will lead the company’s research and preclinical development efforts.
“Luisa is an exceptional scientist whose immunology background focused on drug discovery and translation is truly impressive, and I am thrilled to be reunited with her,” said Sheila Gujrathi, M.D., Chief Executive Officer of Gossamer Bio. “Her collaboration and integration with clinical development makes her the perfect addition at a critically important time for Gossamer Bio. Luisa’s track record of identifying and developing differentiated assets in our core therapeutic areas will bring great long-term value to our company.”
“I am honored to lead the research and scientific efforts at Gossamer Bio,” said Dr. Salter-Cid. “The team and pipeline of innovative and transformative medicines that Gossamer Bio has assembled are truly exciting. I look forward to continuing to grow the portfolio and advancing these novel therapies rapidly to the clinic for patients who are suffering.”
Dr. Salter-Cid brings to Gossamer Bio over 20 years of drug discovery experience in the biotech and pharmaceutical industries. She spent the last 13 years at Bristol Myers Squibb (“BMS”) in increasing positions of responsibility, including Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. In this position, she oversaw several biology groups that focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at BMS, Dr. Salter-Cid led teams that advanced more than 20 compounds into clinical development. She was also Chair of the Immunoscience Target Science Team and a core member of Early Development, Strategy and Licensing teams for both Immunology and Immuno-Oncology. Additionally, she was the scientific lead on several of BMS’ acquisitions and licensing deals and sat on multiple Joint Research Committees and Scientific Advisory Boards. Prior to joining BMS, she was a Senior Project Leader at La Jolla Pharmaceuticals where she led discovery projects. Dr. Salter-Cid also held positions at Genset Corp and Johnson & Johnson. She is an author of over 70 publications and patents and holds a Ph.D. in Immunology from the University of Miami.
About Gossamer Bio:
Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in the autoimmune, allergy/inflammation and immuno-oncology disease areas. Our goal is to improve the lives of patients suffering from disease. We aim to create a business that allows value creation and capture at the individual asset level, long-term sustainability, and continuity. More information can be found at www.gossamerbio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180905005102/en/
CONTACT: Gossamer Bio, Inc.
Chief Financial Officer
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Gossamer Bio, Inc.
Copyright Business Wire 2018.
PUB: 09/05/2018 08:00 AM/DISC: 09/05/2018 08:01 AM